Abstract 1173P
Background
Acral melanoma (AM) is the most common subtype of Chinese melanoma population, taking up over 50%-60%. Compared to cutaneous melanoma, AM is lack of frequent driven mutation like BRAF alternation which only occurs around 10%. Meanwhile, 10%-15% of AM can harbor NRAS mutation. This single-center retrospective study aims to investigate the survival impact of NRAS mutant status on Chinese AM after receiving radical surgery.
Methods
We retrospectively collected AM patients who received radical surgery in Fudan University Shanghai Center with confirmative genomic information from 2017 to 2021. Information of clinicopathologic factors and recurrence and survival outcomes was retrieved from patients document database of our hospital.
Results
Totally 317 patients were recruited in our study.170 (53.6%) were males and median age was 62 years old (range 26-89). 281 (88.6%) cases had primary lesion at lower extremity. The mean Breslow thickness were 3.9mm and ulceration rate was 65.9%. According to AJCC 8th staging system, there were 12% Stage I, 32.2% Stage II and 55.8% Stage III. Genomic alternation occured included 71(22.4%) NRAS, 36 (11.4%) BRAF, 33 (10.4%) KIT and the other 177 (55.8%) widetype of these three genes. No statistical difference was observed in most of clinicopathologic factors between NRAS-mut and NRAS-wt patients. However, NRAS-mut group had higher risk of nodal metastasis beyond 1st tier basin (42.3% vs 27.2, P<0.002).With median follow-up of 22 months, NRAS-mut patients had significantly worse relapse-free survival (RFS, P<0.0001) and overall survival (OS, P=0.010). Distant metastasis-free survival (DMFS) was also numerically reduced but not reached significance (P=0.074). Multivariate analysis showed NRAS mutation was an independent prognostic factors for both RFS (P=0.008) and OS (P=0.025).Among patients receiving adjuvant anti-PD1 monotherapy, median RFS time was significantly worse for NRAS-mut patients (9 months vs 26 months, P<0.0001).
Conclusions
In conclusion, AM harboring NRAS mutation had higher risk of relapse and death as well as reduced efficacy of adjuvant anti-PD1 monotherapy compared to NRAS-wt after radical surgery. NRAS mutation was an independent prognostic factor for resectable Chinese AM population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was funded by Shanghai Science and Technology Development Funds, grant number 9411951700; LinGang laboratory “Seeking Distinguished Young Scholars” project, grant number LG-QS-202205-11; National Natural Science Foundation of China, grant number 81802636.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13